alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### § 209.2 Definitions.

For the purposes of this part, the following definitions apply:

*Act* means the Federal Food, Drug, and Cosmetic Act (sections 201-907 (21 U.S.C. 301-397)).

*Authorized dispenser* means an individual licensed, registered, or otherwise permitted by the jurisdiction in which the individual practices to provide drug products on prescription in the course of professional practice.

*Consumer medication information* means written information voluntarily provided to consumers by dispensing pharmacists as part of patient medication counseling activities.

*Medication Guide* means FDA-approved patient labeling conforming to the specifications set forth in part 208 of this chapter and other applicable regulations.

*Pharmacy* includes, but is not limited to, a retail, mail order, Internet, hospital, university, or clinic pharmacy, or a public health agency, regularly and lawfully engaged in dispensing prescription drugs.

*Side effects statement* means the following verbatim statement: “Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.”
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

      ( print page 9910)    
Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:*                         National Institute of Child Health and Human Development Special Emphasis Panel, Laboratory Support for the Division of Epidemiology, Statistics and Prevention-I and II.                    

*Date:*                         March 24, 2010.                    

*Time:*                         2 p.m. to 3:30 p.m.                    

*Agenda:*                         To provide concept review of proposed concept review.                    

*Place:*                         National Institutes of Health, 6100 Executive Boulevard, Room 5B01, Rockville, MD 20852. (Telephone Conference Call.)                    

*Contact Person:*                         Sathasiva B. Kandasamy, PhD, Scientific Review Officer, Division of Scientific Review, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6100 Executive Boulevard, Room 5B01, Bethesda, MD 20892-9304. (301) 435-6680.                        *skandasa@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: February 25, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-4481 Filed 3-3-10; 8:45 am]

BILLING CODE 4140-01-P
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS WHICH ARE INCLUDED IN THE
REGISTRANT'S FORM 10-Q FOR THE PERIOD ENDED 3/31/00 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.

</LEGEND>
<CIK>                         814241
<NAME>                        Formica Corporation
<MULTIPLIER>                                          1,000
<CURRENCY>                                     U.S. DOLLARS

<S>                              <C>
<PERIOD-TYPE>                                        3-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-START>                                  JAN-1-2000
<PERIOD-END>                                   MAR-31-2000
<EXCHANGE-RATE>                                          1
<CASH>                                               7,300
<SECURITIES>                                             0
<RECEIVABLES>                                       87,100
<ALLOWANCES>                                         4,600
<INVENTORY>                                        119,800
<CURRENT-ASSETS>                                   237,100
<PP&E>                                             342,400
<DEPRECIATION>                                      41,400
<TOTAL-ASSETS>                                     706,400
<CURRENT-LIABILITIES>                              124,600
<BONDS>                                            369,700
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                               100
<OTHER-SE>                                          58,400
<TOTAL-LIABILITY-AND-EQUITY>                       706,400
<SALES>                                            141,100
<TOTAL-REVENUES>                                   141,100
<CGS>                                              103,400
<TOTAL-COSTS>                                      103,400
<OTHER-EXPENSES>                                    44,200
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                  10,000
<INCOME-PRETAX>                                    (15,900)
<INCOME-TAX>                                           900
<INCOME-CONTINUING>                                (16,800)
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                       (16,800)
<EPS-BASIC>                                              0
<EPS-DILUTED>                                            0



</TABLE>
# C_2014388EN.01003102.xml

| 3.11.2014 | EN | Official Journal of the European Union | C 388/31 |
| --- | --- | --- | --- |

3.11.2014

EN

Official Journal of the European Union

C 388/31

---

Action brought on 7 August 2014 — ZZ v Parliament

(Case F-79/14)

2014/C 388/40

Language of the case: French

Parties

Parties

Applicant: ZZ (represented by: A. Lamamra and K. Evora, lawyers)

Applicant:

Defendant: European Parliament

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

Annulment of the decision to withdraw the benefit of the household allowance, with retroactive effect, after the applicant’s transfer to another institution and to limit the amount of the installation allowance to one month instead of two.

Form of order sought

Form of order sought

| — | Annul the decision of the European Parliament of 5 December 2013; |
| --- | --- |

—

Annul the decision of the European Parliament of 5 December 2013;

| — | Annul the decision of the European Parliament of 8 May 2014, rejecting his claim; |
| --- | --- |

—

Annul the decision of the European Parliament of 8 May 2014, rejecting his claim;

| — | Order the Parliament to pay the costs. |
| --- | --- |

—

Order the Parliament to pay the costs.

---
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3360 Lymphocytic choriomeningitis virus serological reagents. ( a ) *Identification.* Lymphocytic choriomeningitis virus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to lymphocytic choriomeningitis virus in serum. The identification aids in the diagnosis of lymphocytic choriomeningitis virus infections and provides epidemiological information on diseases caused by these viruses. Lymphocytic choriomeningitis viruses usually cause a mild cerebral meningitis (inflammation of membranes that envelop the brain) and occasionally a mild pneumonia, but in rare instances may produce severe and even fatal illnesses due to complications from cerebral meningitis and pneumonia.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 65 FR 2311, Jan. 14, 2000]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5510 Immunoglobulins A, G, M, D, and E immunological test system. ( a ) *Identification.* An immunoglobulins A, G, M, D, and E immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the immunoglobulins A, G, M, D, an E (serum antibodies) in serum. Measurement of these immunoglobulins aids in the diagnosis of abnormal protein metabolism and the body's lack of ability to resist infectious agents.
( b ) *Classification.* Class II (performance standards).
#### § 822.5 How will I know if I must conduct postmarket surveillance?

We will send you a letter (the postmarket surveillance order) notifying you of the requirement to conduct postmarket surveillance. Before we send the order, or as part of the order, we may require that you submit information about your device that will allow us better to define the scope of a surveillance order. We will specify the device(s) subject to the surveillance order and the reason that we are requiring postmarket surveillance of the device under section 522 of the act. We will also provide you with any general or specific guidance that is available to help you develop your plan for conducting postmarket surveillance.
# C_2014315EN.01003601.xml

| 15.9.2014 | EN | Official Journal of the European Union | C 315/36 |
| --- | --- | --- | --- |

15.9.2014

EN

Official Journal of the European Union

C 315/36

---

Request for a preliminary ruling from the Finanzgericht Düsseldorf (Germany) lodged on 11 June 2014 — CM Eurologistik GmbH v Hauptzollamt Duisburg

(Case C-283/14)

2014/C 315/58

Language of the case: German

Referring court

Referring court

Finanzgericht Düsseldorf

Parties to the main proceedings

Parties to the main proceedings

Applicant: CM Eurologistik GmbH

Applicant:

Defendant: Hauptzollamt Duisburg

Defendant:

Question referred

Question referred

Must Council Implementing Regulation (EU) No 158/2013 of 18 February 2013 reimposing a definitive anti-dumping duty on imports of certain prepared or preserved citrus fruits (namely mandarins, etc.) originating in the People’s Republic of China (1) be regarded as valid?

1

---

(1)  OJ 2013 L 49, p. 29.

1

---
IN THE SUPREME COURT OF PENNSYLVANIA

WESTERN DISTRICT

JENNIFER M. STRAW AND THOMAS P. 

STRAW, INDIVIDUALLY AND AS COADMINISTRATORS OF THE ESTATE OF 

ELIJAH C. STRAW, DECEASED; AND 

ROWAN J. STRAW, A MINOR, BY AND 

THROUGH HIS PARENTS AND 

NATURAL GUARDIANS, JENNIFER M. 

STRAW AND THOMAS P. STRAW.

v.

KIRK A. FAIR AND GOLON MASONRY 

RESTORATION, INC.

v.

PITTSBURGH LUBES, INC. D/B/A JIFFY 

LUBE, TOWER AUTO SALES & 

SERVICE, NATIONAL AUTOMOTIVE 

PARTS ASSOCIATION-NAPA AUTO 

PARTS T/D/B/A NAPA

v.

THOMAS P. STRAW

PETITION OF: TOWER AUTO SALES & 

SERVICE AND JOHN R. FANTO

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

No. 322 WAL 2018

Petition for Allowance of Appeal from 

the Order of the Superior Court

JENNIFER M. STRAW AND THOMAS P. 

STRAW, INDIVIDUALLY AND AS COADMINISTRATORS OF THE ESTATE OF 

ELIJAH C. STRAW, DECEASED; AND 

ROWAN J. STRAW, A MINOR, BY AND 

THROUGH HIS PARENTS AND 

:

:

:

:

:

:

No. 323 WAL 2018

Petition for Allowance of Appeal from 

the Order of the Superior Court
[322 WAL 2018 and 323 WAL 2018] - 2

NATURAL GUARDIANS, JENNIFER M. 

STRAW AND THOMAS P. STRAW

v.

KIRK A. FAIR AND GOLON MASONRY 

RESTORATION, INC.

v.

PITTSBURGH LUBES, INC. D/B/A JIFFY 

LUBE, TOWER AUTO SALES & 

SERVICE, NATIONAL AUTOMOTIVE 

PARTS ASSOCIATION-NAPA AUTO 

PARTS T/D/B/A NAPA

v.

THOMAS P. STRAW

PETITION OF: TOWER AUTO SALES & 

SERVICE AND JOHN R. FANTO

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

ORDER

PER CURIAM

AND NOW, this 15th day of February, 2019, the Petition for Allowance of Appeal

is DENIED.
Exhibit 31.2
**CERTIFICATION REQUIRED BY RULE 13a-14(a) OR RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934**
I, James E. Winslow, Executive Vice President and Chief Financial Officer of Home ProductsInternational, Inc., certify that:
          1. I have reviewed this quarterly report on Form 10-Q of Home Products International, Inc.;
          2. Based on my knowledge, this report does not contain any untrue statement of a materialfact or omit to state a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading with respect to the periodcovered by this report;
          3. Based on my knowledge, the financial statements, and other financial information includedin this report, fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periods presented in this report;
          4. The registrant’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) for the registrant and have:
          a) designed such disclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that material information relating tothe registrant, including its consolidated subsidiaries, is made known to us by others within thoseentities, particularly during the period in which this report is being prepared;
          b) evaluated the effectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of the disclosure controls andprocedures, as of the end of the period covered by this report based on such evaluation; and
          c) disclosed in this report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourthfiscal quarter in the case of an annual report) that has materially affected, or is reasonablylikely to materially affect, the registrant’s internal control over financial reporting; and
          5. The registrant’s other certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the registrant’s auditors and the auditcommittee of the registrant’s board of directors (or persons performing the equivalent functions):
          a) all significant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely to adversely affect theregistrant’s ability to record, process, summarize and report financial information; and
          b) any fraud, whether or not material, that involves management or other employees who have asignificant role in the registrant’s internal control over financial reporting.       Date: May 17, 2005 By: /s/ JAMES E. WINSLOW           James E. Winslow    Executive Vice President and Chief    Financial Officer
# C_2015320EN.01005102.xml

| 28.9.2015 | EN | Official Journal of the European Union | C 320/51 |
| --- | --- | --- | --- |

28.9.2015

EN

Official Journal of the European Union

C 320/51

---

Order of the General Court of 21 July 2015 — Makhlouf v Council

(Joined Cases T-593/14, T-596/14, T-601/14, T-602/14, T-604/14, T-606/14 and T-612/14) (1)

1

(2015/C 320/69)

Language of the case: French

The General Court (single judge) has ordered that the joined cases be removed from the register.

---

(1)  OJ C 361, 13.10.2014.

1

---
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Sickle Cell Disease Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:*                         Sickle Cell Disease Advisory Committee.                    

*Date:*                        March 26, 2010.                    

*Time:*                         8:30 a.m. to 4:30 p.m.                    

*Agenda:*                         Discussion of Programs and Issues.                    

*Place:*                         National Institutes of Health, 6701 Rockledge Drive, 10th Floor, Conference Room 10091, Bethesda, MD 20892.                    

*Contact Person:*                        W. Keith Hoots, Director, Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Suite 9030, Bethesda, MD 20892, 301-435-0080,                         *hootswk@nhlbi.nih.gov.*

                        Information is also available on the Institute's/Center's home page:                         *http:/www.nhlbi.nih.gov/​meetings/​index.htm,*                         where an agenda and any additional information for the meeting will be posted when available.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: February 23, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-4492 Filed 3-3-10; 8:45 am]

BILLING CODE 4140-01-P
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3920 Assayed quality control material for clinical microbiology assays. ( a ) *Identification.* An assayed quality control material for clinical microbiology assays is a device indicated for use in a test system to estimate test precision or to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. This type of device consists of single or multiple microbiological analytes intended for use with either qualitative or quantitative assays.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Premarket notification submissions must include detailed device description documentation and information concerning the composition of the quality control material, including, as appropriate: ( i ) Analyte concentration;
( ii ) Expected values;
( iii ) Analyte source;
( iv ) Base matrix;
( v ) Added components;
( vi ) Safety and handling information; and
( vii ) Detailed instructions for use.
( 2 ) Premarket notification submissions must include detailed documentation, including line data as well as detailed study protocols and a statistical analysis plan used to establish performance, including: ( i ) Description of the process for value assignment and validation.
( ii ) Description of the protocol(s) used to establish stability.
( iii ) Line data establishing precision/reproducibility.
( iv ) Where applicable, assessment of matrix effects and any significant differences between the quality control material and typical patient samples in terms of conditions known to cause analytical error or affect assay performance.
( v ) Where applicable, identify or define traceability or relationship to a domestic or international standard reference material and/or method.
( vi ) Where applicable, detailed documentation related to studies for surrogate controls.
( 3 ) Premarket notification submissions must include an adequate mitigation (e.g., real-time stability program) to the risk of false results due to potential modifications to the assays specified in the device's 21 CFR 809.10 compliant labeling.
( 4 ) Your 21 CFR 809.10 compliant labeling must include the following: ( i ) The intended use of your 21 CFR 809.10(a)(2) and (b)(2) compliant labeling must include the following: ( A ) Assayed control material analyte(s);
( B ) Whether the material is intended for quantitative or qualitative assays;
( C ) Stating if the material is a surrogate control; and
( D ) The system(s), instrument(s), or test(s) for which the quality control material is intended.
( ii ) The intended use in your 21 CFR 809.10(a)(2) and (b)(2) compliant labeling must include the following statement: “This product is not intended to replace manufacturer controls provided with the device.”
( iii ) A limiting statement that reads “Quality control materials should be used in accordance with local, state, federal regulations, and accreditation requirements.”
[82 FR 34850, July 27, 2017]
#### § 801.16 Medical devices; Spanish-language version of certain required statements.

If devices restricted to prescription use only are labeled solely in Spanish for distribution in the Commonwealth of Puerto Rico where Spanish is the predominant language, such labeling is authorized under § 801.15(c).